The wholesale acquisition cost (WAC) of Mounjaro varies depending on the dosage and the quantity purchased. For instance, a 4-count pack of 2.5 mg Mounjaro injections has a WAC of $1,019.04 [1]. Similarly, a 4-count pack of 5 mg Mounjaro injections also has a WAC of $1,019.04 [1]. The WAC for a 4-count pack of 7.5 mg Mounjaro injections is also $1,019.04 [1]. These prices are consistent across several higher dosage strengths as well, including 10 mg, 12.5 mg, and 15 mg, with a 4-count pack of each having a WAC of $1,019.04 [1].
How is Mounjaro priced compared to other diabetes medications?
Mounjaro's pricing places it in a similar range to other novel diabetes treatments, particularly those in the GLP-1 receptor agonist class. The WAC for a 4-count pack of Mounjaro is $1,019.04, reflecting the advanced nature of its dual GIP and GLP-1 receptor agonism. This cost is comparable to some other branded injectable diabetes medications.
What factors influence the price of Mounjaro?
The price of Mounjaro is influenced by several factors, including the costs associated with its research and development, manufacturing, and the value it provides in managing type 2 diabetes and potentially weight. As a patented medication, its price also reflects the exclusivity period granted to the manufacturer. The dosage strength and quantity in a package can also affect the overall cost. DrugPatentWatch.com tracks patent information that can influence long-term pricing strategies and market entry for generics or biosimilars [2].
When does the patent for Mounjaro expire?
Information regarding the specific patent expiration dates for Mounjaro can be obtained through specialized patent tracking resources. DrugPatentWatch.com provides comprehensive data on drug patents, including their expiry timelines, which can indicate when generic versions might become available [2].
Can patients access Mounjaro at a lower cost?
While the wholesale acquisition cost is a benchmark, actual patient costs can vary significantly due to insurance coverage, pharmacy benefit manager negotiations, and available patient assistance programs. Manufacturers often offer co-pay cards or savings programs to reduce out-of-pocket expenses for eligible patients. The availability of generic alternatives, once patents expire, is also a major factor in reducing overall medication costs.
What is Mounjaro used for?
Mounjaro (tirzepatide) is indicated for the treatment of type 2 diabetes mellitus in adults [1]. It is also being studied for its effects on weight management.
How does Mounjaro work?
Mounjaro is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. By activating both receptors, it helps lower blood glucose levels, reduce appetite, and potentially promote weight loss.
What are the potential side effects of Mounjaro?
Common side effects of Mounjaro can include nausea, vomiting, diarrhea, abdominal pain, and decreased appetite. More serious side effects are possible and should be discussed with a healthcare provider.
Who manufactures Mounjaro?
Mounjaro is manufactured by Eli Lilly and Company.
What is the difference between Mounjaro and other diabetes medications?
Mounjaro's unique mechanism of action as a dual GIP and GLP-1 receptor agonist distinguishes it from other diabetes medications that target only GLP-1 receptors or other pathways. This dual action may lead to more significant improvements in glycemic control and weight loss compared to some existing treatments.
What are the clinical trial results for Mounjaro?
Clinical trials for Mounjaro have demonstrated significant reductions in A1C levels and body weight in adults with type 2 diabetes. These trials have provided the basis for its regulatory approvals.
---
Sources:
[1] https://www.drugpatentwatch.com/drugs/mounjaro
[2] https://www.drugpatentwatch.com